COMMUNIQUÉS West-GlobeNewswire

Humacyte To Announce 2026 Third Quarter Financial Results and Provide Business Update on November 10, 2026
02/11/2026
DURHAM, N.C, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today [...]
Eyconis to Participate in Upcoming Investor Conferences
02/11/2026
REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its [...]
New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation
02/11/2026
MONTREAL and CHARLOTTE, N.C., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular [...]
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
02/11/2026
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately [...]
Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026
02/11/2026
FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of [...]
CytomX Therapeutics to Present at Upcoming November Investor Conferences
02/11/2026
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will [...]
Alfasigma Announces New Linerixibat Data Across PBC and Liver Disease to be Presented at AASLD’s The Liver Meeting 2026
02/11/2026
Five presentations will highlight new analyses of linerixibat in cholestatic pruritus associated with primary biliary cholangitis, including an oral presentation and four posters from the Phase 3 GLISTEN study and real- [...]
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
02/11/2026
WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry
02/11/2026
First plaque tool with prospective outcomes data. Faster, sustained LDL-C control: approximately 50% of patients reached goal by 90 days vs. approximately 35% with CCTA alone. GAMEFILM data highlight high prevalence of [...]
Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study
02/11/2026
The study targets earlier detection, prevention and treatment of Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions including rare dementias FREMONT, Calif. and HELSINKI, Finland, Nov. 02, [...]
Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China
02/11/2026
China Resources Medical Devices to serve as exclusive distributor for Baird’s microwave ablation (MWA) products in 19 markets in the PRC Agreement includes initial purchase order of RMB 6 million ($900,000) NEW YORK, [...]
Alvotech to Present at Upcoming Investor Conferences in November
02/11/2026
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
02/11/2026
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX ® Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1 [...]
ICPO ACADEMY FOR THERANOSTICS Launches Advanced Program in Radiomolecular Precision Oncology
02/11/2026
Online curriculum expands with advanced clinical cases in prostate cancer and neuroendocrine tumors including multidisciplinary tumor board illustrations Wiesbaden, November 2, 2026 – Radiomolecular Precision Oncology, [...]
OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care
02/11/2026
Collaboration will bring diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementation BETHLEHEM, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc [...]
OraSure Technologies rejoint la Coalition mondiale contre la drépanocytose afin de favoriser l’accès à un diagnostic plus précoce et aux soins
02/11/2026
Cette collaboration apportera une expertise en matière de diagnostic à une initiative mondiale multipartite axée sur les politiques publiques, le plaidoyer et la mise en œuvre concrète des mesures. BETHLEHEM, [...]
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer
02/11/2026
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer Promotion follows recent €120 million Series D financing as Nouscom advances NOUS-209 into [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2026
02/11/2026
DIJON, France CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2026
02/11/2026
DIJON, France CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à [...]

Pages